124 related articles for article (PubMed ID: 38558495)
1. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Apr; ():. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
2. PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples.
Ronchi A; Zito Marino F; Moscarella E; Brancaccio G; Argenziano G; Troiani T; Napolitano S; Franco R; Cozzolino I
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328198
[TBL] [Abstract][Full Text] [Related]
3. Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology.
Dermawan JKT; Underwood D; Policarpio-Nicolas ML
Diagn Cytopathol; 2019 Jul; 47(7):653-658. PubMed ID: 30794352
[TBL] [Abstract][Full Text] [Related]
4. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
[TBL] [Abstract][Full Text] [Related]
5. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
6. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall.
Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT
Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630
[TBL] [Abstract][Full Text] [Related]
7. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
[TBL] [Abstract][Full Text] [Related]
8. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
9. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
10. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract.
Smithgall MC; Liu-Jarin X; Chen X; Singh K; Quddus MR; Cimic A
Hum Pathol; 2023 Aug; 138():12-17. PubMed ID: 37209921
[TBL] [Abstract][Full Text] [Related]
13. Staged Excision of Lentigo Maligna of the Head and Neck: Assessing Surgical Excision Margins With Melan A, SOX10, and PRAME Immunohistochemistry.
de Wet J; Plessis PJD; Schneider JW
Am J Dermatopathol; 2023 Feb; 45(2):107-112. PubMed ID: 36669074
[TBL] [Abstract][Full Text] [Related]
14. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience.
Carvajal P; Zoroquiain P
Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245
[TBL] [Abstract][Full Text] [Related]
15. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.
Lezcano C; Pulitzer M; Moy AP; Hollmann TJ; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Apr; 44(4):503-508. PubMed ID: 31633488
[TBL] [Abstract][Full Text] [Related]
18. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]